表紙
市場調查報告書
商品編碼
997850

躁鬱症治療藥的全球市場

Bipolar Disorder Therapeutics

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 380 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球躁鬱症治療藥的市場規模,預計在分析期間(2020年∼2027年)將以1%的年複合成長率增長,從2020年的50億美元,到2027年達到54億美元。

本報告所分析的市場區隔之一的心情穩定藥部門,分析期間中預計將以0.3%的年複合成長率增長,達到5億6,080萬美元。

本報告提供全球躁鬱症治療藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • AbbVie, Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:53公司
目錄
Product Code: MCP-6202

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass Research Platform

» Complimentary updates for one year

Global Bipolar Disorder Therapeutics Market to Reach US$6.8 Billion by the Year 2026

Bipolar disorder (also manic depression or manic depressive disorder) is a severe double-edged psychiatric illness featuring cyclical mood swings of depression and elation. Bipolar disorder is one of the leading brain diseases causing unusual shift in energy, mood, activity levels, and ability to perform daily activities. Bipolar disorders increase the risk of premature death due to several comorbidities such as diabetes, obesity, and cardiovascular diseases. Bipolar disorder is treated with medication in addition to alternative therapies of electro convulsion, stress reduction and counselling. Global market for bipolar disorder therapeutics maintained growth trajectory during 2020 and 2021 as patient treatment programs remained mostly unperturbed by the pandemic. Patient inflows remained resilient during the pandemic period and care givers maintained their focus on effective treatment regimens for their patients. In countries such as the US, a large increase in anxiety disorders including panic attacks and social anxiety, amongst people was observed which eventually led to increased uptake of treatment and medications for curing the same. Moreover, rising focus of government and healthcare institutes on treating mental health problems is also expected to bode well for the market. With increasing competition in the market and technological developments, researchers are concentrating on first generation antipsychotics to gain better knowledge of their functioning

Amid the COVID-19 crisis, the global market for Bipolar Disorder Therapeutics estimated at US$5.6 Billion in the year 2020, is projected to reach a revised size of US$6.8 Billion by 2026, growing at a CAGR of 3.1% over the analysis period. Antipsychotic Drugs, one of the segments analyzed in the report, is projected to grow at a 3% CAGR to reach US$3.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anticonvulsants segment is readjusted to a revised 3.9% CAGR for the next 7-year period. This segment currently accounts for a 21.8% share of the global Bipolar Disorder Therapeutics market. Generally prescribed to treat schizophrenia, antipsychotic drugs have a wider relevance in managing bipolar disorders. In bipolar care, antipsychotic drugs are highly preferred in treating periods of psychosis during mania or severe depression. Anticonvulsant drugs aid in the treatment of bipolar disorder and in managing the mania associated with bipolar disorder. Widely prescribed anticonvulsant drugs for bipolar disorder treatment include carbamazepine (Equetro), divalproex sodium (Depakote), lamotrigine (Lamictal), topiramate (Topamax), and valproic acid (Depakene).

The U.S. Market is Estimated at $2.5 Billion in 2021, While China is Forecast to Reach $513.9 Million by 2026

The Bipolar Disorder Therapeutics market in the U.S. is estimated at US$2.5 Billion in the year 2021. The country currently accounts for a 44.35% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$513.9 Million in the year 2026 trailing a CAGR of 4.8% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR while Rest of European market (as defined in the study) will reach US$243.7 Million by the end of the analysis period. North America leads the world bipolar disorder therapeutics market, supported by the strong awareness of the disease condition, existence of leading companies, technological developments, presence of a strong healthcare system, and increasing number of bipolar disorder cases in the region. Asia, led by India and China, is expected to emerge to be the market with strong growth mainly on account of rising prevalence of mental disorders, improving awareness regarding bipolar disorders, and increasing investments by leading companies.

Mood Stabilizers Segment to Reach $1.2 Billion by 2026

Mood stabilizers are the psychiatric drugs that aid in controlling the swings between mania and depression. These medications are formulated to decrease the brain activity and are prescribed to restore neurochemical balance. In the global Mood Stabilizers segment, USA, Canada, Japan, China and Europe will drive the 2.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$873.6 Million in the year 2020 will reach a projected size of US$1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$104.2 Million by the year 2026, while Latin America will expand at a 3.5% CAGR through the analysis period.

Select Competitors (Total 102 Featured) -

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Janssen Pharmaceutica N.V.
  • Johnson & Johnson Services, Inc.
  • Novartis International AG
  • Otsuka America Pharmaceutical, Inc.
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Validus Pharmaceuticals LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Bipolar Disorder Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Bipolar Disorder Therapeutics - A Prelude
    • Symptoms of Bipolar Disorder
    • Mood Episode - A Major Symptom
    • Manic Episode Vs Depressive Episode
    • Causes of Bipolar Disorder
    • Types of Bipolar Disorder
    • Co-morbidities of Bipolar Disorder
    • Segments
    • Antipsychotic Drugs
    • Antidepressant Drugs
    • Anticonvulsants
    • Mood Stabilizers
    • Anti-Anxiety Drugs
    • Select Drugs for Bipolar Disorder Treatment by Drug Class
    • Impact of Covid-19 and a Looming Global Recession
    • 2020 Marked as a Year of Disruption & Transformation
    • The Never-Ending "Race" Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond?
    • Omicron Spreads Panic Worldwide; Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic
    • Short-term Impact of Omicron on Travel
    • Steps taken by the Countries to Prevent Transmission of Omicron Variant
    • Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
    • With IMF Making an Upward Revision of Global GDP for 2021, Companies Are Bullish About an Economic Comeback Despite a Continuing Pandemic
    • A Strong Yet Exceedingly Patchy & Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • COVID-19 Impact on Bipolar Disorder Therapeutics Market
    • Global Market Analysis and Prospects
    • Bipolar Disorder Therapeutics Market Set to Witness Rapid Growth
    • Regional Market Analysis
    • Treatment Analysis
    • Anti-Psychotics
    • Pipeline Drugs in Phase III for Bipolar Disorder
    • Select Anti-Psychotic Drugs
    • A Review of Anti-Psychotics
    • Indications of Antipsychotics
    • An Effective Adjunctive Therapy
    • Off-label Uses
    • Efficacy - Marred by Lack of Evidence Base
    • Types of Antipsychotics
    • Side Effects of Antipsychotics
    • Symptoms of Antipsychotics Withdrawal
    • Anti-Depressants
    • Market Overview
    • Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
    • Anti-Depressant Treatment
    • Select Top Selling Anti-Depressants in 2018
    • Select Antidepressant Drugs
    • Recent Approvals of Anti-Depressants
    • Pipeline Drugs in Phase III for Depressive Disorder
    • A Review of Depression
    • Types of Depressive Disorders
    • Available Treatment
    • Working of Antidepressants
    • Ranking of Antidepressants in Terms of Efficacy
    • Types of Antidepressants
    • NMDA Receptor Antagonists
    • Acetylcholinesterase Inhibitors
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Serotonin-norepinephrine Reuptake Inhibitors (SNRI)
    • Tricyclic Antidepressants
    • Monoamine Oxidase Inhibitors (MOI)
    • Benzodiazepines
    • Beta Blockers
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Market Gains to Continue Amid Rising Prevalence of Bipolar Disorder
    • Awareness Programs Augment Prospects
    • Increasing R&D Activities Drive the Global Bipolar Disorder Therapeutics Market
    • Technology Advancements Widen Addressable Market
    • Social Inclusion of People with Mental Illnesses Augurs Well
    • Online Self-Management Tools Improve Treatment Outcomes
    • Increasing Product R&D, Approvals & Launches Support Market Expansion
    • Side Effects of Bipolar Disorder Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Bipolar Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
    • TABLE 4: World Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 7: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 10: World Recent Past, Current & Future Analysis for Mood Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Mood Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Mood Stabilizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 13: World Recent Past, Current & Future Analysis for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Antidepressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 16: World Recent Past, Current & Future Analysis for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Anti-anxiety Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
    • TABLE 19: USA Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Canada Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: Canada 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • JAPAN
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
    • TABLE 25: Japan Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Japan Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Japan 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • CHINA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
    • TABLE 28: China Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: China Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: China 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • EUROPE
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
    • TABLE 31: Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: Europe Historic Review for Bipolar Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Europe Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • FRANCE
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
    • TABLE 37: France Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: France Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: France 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • GERMANY
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Germany Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Germany 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • ITALY
    • TABLE 43: Italy Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Italy Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Italy 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • UNITED KINGDOM
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
    • TABLE 46: UK Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: UK Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: UK 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • SPAIN
    • TABLE 49: Spain Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Spain Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Spain 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • RUSSIA
    • TABLE 52: Russia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Russia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Russia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • REST OF EUROPE
    • TABLE 55: Rest of Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Rest of Europe Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Rest of Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • ASIA-PACIFIC
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 59: Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
    • TABLE 61: Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • AUSTRALIA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
    • TABLE 64: Australia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Australia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Australia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • INDIA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
    • TABLE 67: India Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: India Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: India 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • SOUTH KOREA
    • TABLE 70: South Korea Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: South Korea Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: South Korea 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 73: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Rest of Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Rest of Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • LATIN AMERICA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
    • TABLE 76: Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 77: Latin America Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
    • TABLE 79: Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Latin America Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • ARGENTINA
    • TABLE 82: Argentina Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Argentina Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Argentina 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • BRAZIL
    • TABLE 85: Brazil Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Brazil Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Brazil 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • MEXICO
    • TABLE 88: Mexico Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Mexico Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Mexico 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • REST OF LATIN AMERICA
    • TABLE 91: Rest of Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Latin America Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • MIDDLE EAST
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
    • TABLE 94: Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 95: Middle East Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
    • TABLE 97: Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Middle East Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • IRAN
    • TABLE 100: Iran Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Iran Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Iran 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • ISRAEL
    • TABLE 103: Israel Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Israel Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Israel 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • SAUDI ARABIA
    • TABLE 106: Saudi Arabia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Saudi Arabia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Saudi Arabia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 109: UAE Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UAE Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: UAE 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • REST OF MIDDLE EAST
    • TABLE 112: Rest of Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Rest of Middle East Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Rest of Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
  • AFRICA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
    • TABLE 115: Africa Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Africa Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Africa 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 102